VTRS
Viatris Inc

3,775
Mkt Cap
$17.15B
Volume
19.84M
52W High
$14.60
52W Low
$6.85
PE Ratio
-4.71
VTRS Fundamentals
Price
$15.56
Prev Close
$14.58
Open
$14.76
50D MA
$12.32
Beta
0.78
Avg. Volume
8.5M
EPS (Annual)
-$0.5315
P/B
1.11
Rev/Employee
$459,678.13
Loading...
Loading...
News
all
press releases
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 Viatris to Report Fourth Quarter and Full Year 2025 Financial...
PR Newswire·6d ago
News Placeholder
More News
News Placeholder
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Viatris Appoints Matthew J. Maletta as Chief Legal Officer Viatris Appoints Matthew J. Maletta as Chief Legal Officer PR Newswire PITTSBURGH, Feb. 3, 2026 Brian Roman to Leave the Company After More...
PR Newswire·7d ago
News Placeholder
What Does the Market Think About Viatris Inc?
read more...
Benzinga·11d ago
News Placeholder
Viatris Launches Inpefa To Treat Heart Failure In UAE
(RTTNews) - Viatris Inc. (VTRS), a healthcare company, Tuesday announced the launch of Inpefa or sotagliflozin in the United Arab Emirates or UAE, which is the first country within the Viatris...
Nasdaq News: Markets·21d ago
News Placeholder
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa (Sotagliflozin) for the Treatment of Heart Failure
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa (Sotagliflozin) for the Treatment of Heart Failure Viatris Expands Innovative Portfolio in...
PR Newswire·21d ago
News Placeholder
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer PR Newswire PITTSBURGH, Jan. 8, 2026...
PR Newswire·1mo ago
News Placeholder
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?
Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
How Is The Market Feeling About Viatris Inc?
read more...
Benzinga·2mo ago
News Placeholder
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.
Zacks·2mo ago
News Placeholder
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire PITTSBURGH, Dec. 17, 2025 PITTSBURGH, Dec...
PR Newswire·2mo ago
<
1
2
...
>

Latest VTRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.